Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v3-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2024-09-24 | 2023-08-02 |
| Drug Identification Number | 02139529 | 02139529 |
| Brand name | SODIUM ACETATE INJECTION, USP | SODIUM ACETATE INJECTION, USP |
| Common or Proper name | SODIUM ACETATE INJECTION, USP | SODIUM ACETATE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | SODIUM ACETATE | SODIUM ACETATE |
| Strength(s) | 328MG | 328MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 50 mL | 50 mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-08-01 | 2023-08-01 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | The long-term supply status is currently unknown; however, we assure you that we are working diligently with our suppliers on a resolution. | Fresenius Kabi Canada would like to advise that our Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL will be removed off allocation effective June 1, 2023. This product will be available to all customers without restrictions. Our inventory is expected to be depleted by August 1, 2023, after which, the long-term supply status is still unknown. |
| Health Canada comments |